-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-function_executive.pdf
August 01, 2014 - Non-ACS conditions can
include noncoronary causes (e.g., sepsis, congestive heart
failure, myocarditis, drug … Food and Drug Administration approved the
measurement of troponin T in dialysis patients for the
express … Food and Drug Administration
approved the measurement of troponin T in dialysis
patients for the express … Regarding CKD patients without suspected ACS, our
findings support the current Food and Drug Administration
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-translation-c-diff-treatment-clinical-pathway.pdf
November 01, 2019 - diagnosing C. diff.
18) Does the recommendation specify patient
characteristics (such as coincident drug … trigger the thought.
18) Does the recommendation specify patient
characteristics (such as coincident drug … Recommendations
18) Does the recommendation specify patient
characteristics (such as coincident drug
-
effectivehealthcare.ahrq.gov/products/health-data-mapping/protocol
December 03, 2019 - Food and Drug Administration [FDA]), and relevant professional societies (e.g. the American Health Information
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/gout_research-protocol-2014.pdf
January 01, 2014 - Some 32 percent of the costs were attributed to gouty arthritis attacks, and drug
expenditures accounted
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-generated-health-data-protocol-chronic-conditions.pdf
March 17, 2020 - Food and Drug Administration [FDA]), and relevant professional societies
(e.g. the American Health Information
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/pain-chronic_research-protocol.pdf
July 28, 2010 - Evidence-based Practice Center Technical Brief Protocol
Source: www.effectivehealthcare.ahrq.gov
Published Online: July 28, 2010
1
Evidence-based Practice Center Technical Brief Protocol
Project Title: Technical Brief - Multidisciplinary Pain Programs for Chronic
Non-Cancer Pain
I. Background an…
-
effectivehealthcare.ahrq.gov/products/medical-evidence-communication/research-protocol
July 31, 2012 - Negative (loss) frame: “With drug X, you have a 5% chance of dying” vs. … “With drug X, you have a 95% chance of surviving.”
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-ovarian-contraceptives_executive.pdf
June 01, 2013 - We invited
drug manufacturers to submit additional information
through a scientific information packets … Manual searching and contacts
with drug manufacturers via the scientific information
packet requests
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-masks-prevention-covid-version-1.pdf
December 01, 2021 - Infect Disord Drug Targets. 2014;14(2):110-6. doi:
10.2174/1871526514666141021112855. … Infect
Disord Drug Targets. 2014;14(2):110-6. doi:
10.2174/1871526514666141021112855.
-
effectivehealthcare.ahrq.gov/products/mental-health-substance-abuse/research
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/menopause_disposition-comments.pdf
March 05, 2015 - consider when making clinical recommendations about relative
efficacy of hormonal vs. nonhormonal drug
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/vte-prophyalaxis_disposition-comments.pdf
May 29, 2013 - well as this
group are at higher risk for DVT and also at higher risk for bleeding due to potential
drug … antiplatelet therapy, renal failure, and bariatric surgery is clear to me since the
risks of anticoagulant drug-based
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/medical-evidence-communication_research-protocol.pdf
July 31, 2012 - o Negative (loss) frame: “With drug X, you have a 5%
chance of dying” vs. … “With drug X, you have a 95%
chance of surviving.”
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/trauma-child-interventions_research-protocol.pdf
March 26, 2012 - emotional abuse (11%), physical abuse (28%), sexual abuse (21%), battered mother (13%),
household drug
-
effectivehealthcare.ahrq.gov/products/antibiotics-respiratory-infection/research-protocol/
-
effectivehealthcare.ahrq.gov/products/asthma-treatment/research-protocol
January 27, 2011 - Food and Drug Administration Medical and Statistical Reviews and Authorized Medicines for the European
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/worker-health_research-protocol.pdf
May 26, 2015 - , quality of life, stress or
distress
o KQ 2b: Intermediate outcomes: Tobacco, alcohol or other drug
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-risk-assessment-genes_executive.pdf
July 01, 2012 - Prostate-specific antigen (PSA) was approved by the US
Food and Drug Administration in 1986 for monitoring
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/stem-cell-children_executive.pdf
February 01, 2012 - mortality, secondary malignancies),
moderate-strength evidence suggests that extended
periods of drug-free
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/behavior-change_research.pdf
August 01, 2015 - Reviews of behavior change interventions often face a greater data extraction burden than
reviews of drug … At a very practical level this occurs, for example, when a drug can
be described by a limited set of … Unlike drug
studies (but often similar to surgical or medical device interventions), the qualifications